<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02423941</url>
  </required_header>
  <id_info>
    <org_study_id>616.36-089.843-008.6-07-037</org_study_id>
    <nct_id>NCT02423941</nct_id>
  </id_info>
  <brief_title>A Study of Retrograde rEperfusion in Dbd Donor LIver Transplantation</brief_title>
  <acronym>REDLIT</acronym>
  <official_title>A Randomized Clinical Study of Retrograde Caval or Antegrade Portal Reperfusion for Early Graft Dysfunction Prevention in Deceased Brain Dead Donor Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Republican Scientific and Practical Center for Organ and Tissue Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Republican Scientific and Practical Center for Organ and Tissue Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether retrograde caval reperfusion of liver graft could be superior over
      antegrade portal reperfusion in regard of incidence and severity of early allograft liver
      dysfunction.

      All eligible enrolled liver transplant candidates will be randomized to receive either:

        1. retrograde caval, followed by sequential portal-arterial, reperfusion or

        2. antegrade, sequential portal-arterial reperfusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that retrograde caval reperfusion could be superior over antegrade portal
      reperfusion in regard of incidence and severity of early allograft liver dysfunction.

      Chi-square method of sample size estimation with a=0,05, b=0,20 and P1-P2 = 0,25 required a
      41 subject per group (Stephen B Hulley, Steven R Cummings, Warren S Browner, Deborah G Grady,
      Thomas B Newman.-4th ed. Lippincott Williams &amp; Wilkins, 2013).

      After signing the informed consent 90 patients will be randomized to study and active-control
      group (45 each).

      Only patients undergoing classical technique (retrohepatic IVC resection) of liver
      transplantation without vena-venous bypass will be enrolled to the study.

      In the study group after completion of both caval anastomoses (super and infra-hepatic) the
      infra-hepatic cava-clamp is released and removed allowing the filling and flushing the liver
      retrogradely through the hepatic veins. 300 ml of blood is drained via donor portal vein and
      the vein will be clamped.

      Suprahepatic cava-clamp is released and removed allowing venous return to the right atrium.

      Portal vein anastomosis will be constructed. Before the last 2-3 stitches another 100 ml will
      be drained retrogradely. Recipient portal vein clamp is removed and liver will be reperfused
      antegradely. After that arterial and biliary anastomoses will be constructed.

      In the control group cava-clamps are not removed until completion the portal vein
      anastomosis.

      Chi-square test and regression analysis will be used to test the difference in incidence of
      early allograft liver dysfunction in the study groups.

      Mann-Whitney test will be used to compare the median of highest aspartate aminotransferase
      (AST) and alanine aminotransferase (ALT) levels 24 and 48 hours post-reperfusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of early graft dysfunction (EAD)</measure>
    <time_frame>1-7 postoperative days</time_frame>
    <description>EAD will be assessed according to Olthoff KM, et al. Liver Transpl. 2010. Severe EAD will be assessed according to P.R. Salvalaggio, et al. Transplantation Proceedings, 2012.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels</measure>
    <time_frame>24 and 48 hours post reperfusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biliary strictures (anastomotic and nonanastomotic)</measure>
    <time_frame>90 days after liver transplant procedure</time_frame>
    <description>All biliary strictures would be diagnosed by cholangiography, either ERCP or MRCP. Ulrtrasound will be used as a screening tool to assign a cholestatic patient to cholangiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital mortality</measure>
    <time_frame>90 days after liver transplant procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Liver Transplantation</condition>
  <condition>Reperfusion</condition>
  <condition>Delayed Graft Function</condition>
  <arm_group>
    <arm_group_label>Retrograde reperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the transplant procedure the liver is initially reperfused retrogradely via hepatic veins. Venting of 300 ml blood is allowed via donor portal vein. After completion the portal vein anastomosis and retrograde venting of another 100 ml blood the antegrade portal reperfusion is performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antegrade reperfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Retrogade reperfusion</intervention_name>
    <description>Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.</description>
    <arm_group_label>Retrograde reperfusion</arm_group_label>
    <other_name>Caval reperfusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Antegrade reperfusion</intervention_name>
    <description>Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.</description>
    <arm_group_label>Antegrade reperfusion</arm_group_label>
    <other_name>Conventional sequential portal-arterial reperfusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Donor Inclusion Criteria:

          -  deceased brain dead

          -  age 18-59

          -  length of ICU treatment up to 7 days

          -  highest AST and ALT up to 200 UI/L

          -  macroscopic steatosis up to 30%

          -  highest serum sodium up to 165 mmol/L

          -  highest bilirubin 25 µmol/L

          -  application of norepinephrine is allowed

          -  preservation solution - HTK (Custodiol)

        Recipient inclusion Criteria:

          -  age 18-69

          -  primary liver transplant

          -  full-size transplant

        Technique of liver transplant:

          -  with IVC resection;

          -  without veno-venous bypass;

          -  sequential portal-arterial reperfusion

          -  flushing of portal vascular bed with 500 ml of called to 2-4 °C saline at back-table
             before implantataion

        Recipient exclusion Criteria:

          -  live donor liver transplant

          -  reduced and split grafts;

          -  multi organ failure (including fulminant and UNOS status 1);

          -  fulminant hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oleg O Rummo, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>RSPC for organ and tissue transplantation, Minsk 9th clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aliaksei E Shcherba, PhD</last_name>
    <phone>+375293330689</phone>
    <email>aleina@tut.by</email>
  </overall_contact>
  <location>
    <facility>
      <name>RSPC for organ and tissue transplantation, Minsk 9th clinic</name>
      <address>
        <city>Minsk</city>
        <zip>220116</zip>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aliaksei E Shcherba, PhD</last_name>
      <phone>+375293330689</phone>
      <email>aleina@tut.by</email>
    </contact>
    <contact_backup>
      <last_name>Denis F Efimov</last_name>
      <phone>+375(29)6884415</phone>
      <email>den.efimoff@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aliaksei E Shcherba, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew F Minou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evgeni O Santotski</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander M Dzyadzko, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis J Efimov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergei V Korotkov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oleg O Rummo, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belarus</country>
  </location_countries>
  <reference>
    <citation>Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, Christie JD. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010 Aug;16(8):943-9. doi: 10.1002/lt.22091.</citation>
    <PMID>20677285</PMID>
  </reference>
  <reference>
    <citation>Salvalaggio P, Afonso RC, Felga G, Ferraz-Neto BH. A proposal to grade the severity of early allograft dysfunction after liver transplantation. Einstein (Sao Paulo). 2013 Jan-Mar;11(1):23-31. English, Portuguese.</citation>
    <PMID>23579740</PMID>
  </reference>
  <reference>
    <citation>Designing Clinical Research/Stephen B Hulley, Steven R Cummings, Warren S Browner, Deborah G Grady, Thomas B Newman.-4th ed. Lippincott Williams &amp; Wilkins, 2013.-367p.]</citation>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2015</study_first_submitted>
  <study_first_submitted_qc>April 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2015</study_first_posted>
  <last_update_submitted>December 31, 2016</last_update_submitted>
  <last_update_submitted_qc>December 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Transplantation</keyword>
  <keyword>Retrograde Reperfusion</keyword>
  <keyword>Graft dysfunction</keyword>
  <keyword>Randomized study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

